BRUKER CORPORATION Proceeds from Sale and Maturity of Marketable Securities
BRUKER CORPORATION (BRKR) reported Proceeds from Sale and Maturity of Marketable Securities of $186.80 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-16.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2018-03-16
- BRUKER CORPORATION proceeds from sale and maturity of marketable securities for the quarter ending 2017-12-31 was $52.80M, a 23.94% increase year-over-year.
- BRUKER CORPORATION proceeds from sale and maturity of marketable securities for the quarter ending 2017-09-30 was $64.60M, a 10.65% decline year-over-year.
- BRUKER CORPORATION proceeds from sale and maturity of marketable securities for the quarter ending 2017-06-30 was $10.70M, a 62.32% decline year-over-year.
- BRUKER CORPORATION proceeds from sale and maturity of marketable securities for the quarter ending 2017-03-31 was $58.70M, a 170.51% increase year-over-year.
- BRUKER CORPORATION proceeds from sale and maturity of marketable securities for fiscal 2017 was $186.80M, a 13.21% increase from fiscal 2016.
- BRUKER CORPORATION proceeds from sale and maturity of marketable securities for fiscal 2016 was $165.00M, a 39.01% increase from fiscal 2015.
- BRUKER CORPORATION proceeds from sale and maturity of marketable securities for fiscal 2015 was $118.70M, a 524.74% increase from fiscal 2014.
- BRUKER CORPORATION proceeds from sale and maturity of marketable securities for fiscal 2014 was $19.00M.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 3 month as first filed | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|---|
| 2017-12-31 | $52.80M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $117.40M derived: sum of 2 quarters · filed 2018-03-16 | $128.10M derived: sum of 3 quarters · filed 2018-03-16 | $186.80M 10-K · filed 2018-03-16 | |
| 2017-09-30 | $64.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $75.30M derived: sum of 2 quarters · filed 2017-11-09 | $134.00M 10-Q · filed 2017-11-09 | $176.60M derived: sum of 4 quarters · filed 2018-03-16 | |
| 2017-06-30 | $10.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $69.40M 10-Q · filed 2017-08-09 | $112.00M derived: sum of 3 quarters · filed 2018-03-16 | $184.30M derived: sum of 4 quarters · filed 2018-03-16 | |
| 2017-03-31 | $58.70M 10-Q · filed 2017-05-10 | $101.30M derived: sum of 2 quarters · filed 2018-03-16 | $173.60M derived: sum of 3 quarters · filed 2018-03-16 | $202.00M derived: sum of 4 quarters · filed 2018-03-16 | |
| 2016-12-31 | $42.60M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $114.90M derived: sum of 2 quarters · filed 2018-03-16 | $143.30M derived: sum of 3 quarters · filed 2018-03-16 | $165.00M 10-K · filed 2018-03-16 | |
| 2016-09-30 | $72.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $100.70M derived: sum of 2 quarters · filed 2017-11-09 | $122.40M 10-Q · filed 2017-11-09 | $199.80M derived: sum of 4 quarters · filed 2018-03-16 | |
| 2016-06-30 | $28.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $50.10M 10-Q · filed 2017-08-09 | $127.50M derived: sum of 3 quarters · filed 2018-03-16 | $128.50M derived: sum of 4 quarters · filed 2018-03-16 | |
| 2016-03-31 | $21.70M 10-Q · filed 2017-05-10 | $99.10M derived: sum of 2 quarters · filed 2018-03-16 | $100.10M derived: sum of 3 quarters · filed 2018-03-16 | $118.90M derived: sum of 4 quarters · filed 2018-03-16 | |
| 2015-12-31 | $77.40M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $78.40M derived: sum of 2 quarters · filed 2018-03-16 | $97.20M derived: sum of 3 quarters · filed 2018-03-16 | $118.70M 10-K · filed 2018-03-16 | |
| 2015-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $19.80M derived: sum of 2 quarters · filed 2016-11-09 | $41.30M 10-Q · filed 2016-11-09 | ||
| 2015-06-30 | $18.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | $40.30M 10-Q · filed 2016-08-05 | |||
| 2015-03-31 | $21.50M 10-Q · filed 2016-05-06 | -$21.50M 10-Q · filed 2015-05-08 | |||
| 2014-12-31 | $19.00M 10-K · filed 2017-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avantor, Inc. (AVTR) | United States | $10.501B | -9.72 |
| REVVITY, INC. (RVTY) | United States | $16.814B | 53.44 |
| Alamar Biosciences, Inc. (ALMR) | United States | $2.300B | |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |